[{"id":"eff415a5-52c4-4898-ac00-39b39e5eb5e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00518206","created_at":"2021-03-25T14:39:50.052Z","updated_at":"2024-07-02T16:36:01.934Z","phase":"Phase 2","brief_title":"Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma","source_id_and_acronym":"NCT00518206","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CD8 • CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • NY-ESO-1 Iscomatrix • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/28/2003","start_date":" 11/28/2003","primary_txt":" Primary completion: 01/22/2010","primary_completion_date":" 01/22/2010","study_txt":" Completion: 01/22/2010","study_completion_date":" 01/22/2010","last_update_posted":"2022-10-25"},{"id":"ebe7e46d-6b06-4126-a1c0-ee83334b5136","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199901","created_at":"2021-03-25T14:15:52.613Z","updated_at":"2024-07-02T16:36:02.690Z","phase":"Phase 2","brief_title":"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma","source_id_and_acronym":"NCT00199901","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NY-ESO-1 Iscomatrix"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2022-10-11"}]